International law firm Watson Farley & Williams (“WFW”) advised Principia SGR S.p.A. (“Principia”) – via its “Principia III – Health” fund – on its investment in the capital of Clinical Trial Center S.p.A., a company formed following the spin-off by Rome’s Agostino Gemelli University Polyclinic (“Gemelli Foundation”) of its clinical trials and biomedical research business.
Principia SGR is one of Italy’s leading venture capital firms, responsible for creating several investment funds over the years, including Principia III-Health whose focus is on start-ups and innovative small and medium-sized enterprises (SMEs) operating in the healthcare sector.
The Clinical Trial Center was created approximately four years ago by the Gemelli Foundation with the aim of improving clinical research management by offering services comprising both the “Site Management Organization (SMO)” and “Contract Research Organization (CRO)”, as well as providing experimenters with specific training on “Good Clinical Practice (GCP)” in the study of new medicines and devices.
The underlying goal of Principia’s investment is to support the growth of the Clinical Trial Center business by allowing a tangible acceleration in the development of SMO and CRO services for pharmaceutical companies and institutions of clinical research.
The WFW Italy team advising Principia was led by Corporate Counsel Carlo Cosmelli.
